Loading…
Employees: 109
Size Cullinan Therapeutics (CGEM) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $728M, the 2451st largest of 3,117 United States companies the cockpit tracks. Shares closed at $11.31 on 6 Nov 2026.
Performance Over six months the shares fell 22.3%, against -13.3% for the median peer and -1.1% for the United States market (cap-weighted) — 8th lowest of 21 in its peer set.
Short interest Short interest is 11.9% of the free float (15 Oct 2026).
Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$316,000 | -$311,000 | -$306,000 | -$310,000 | -$93,000 |
| EBITDA | -$221M | -$241M | -$197M | -$190M | -$132M |
| Net income | -$205M | -$220M | -$167M | -$153M | $111M |
| Free cash flow | n/a | -$176M | -$145M | -$134M | -$128M |
| Capital expenditure | $0 | $49,000 | $0 | $208,000 | $1.13M |
| Total debt | $2.07M | $2.68M | $2.15M | $3.59M | $5.01M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CGEM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -26.8% | -6.5% | 2nd lowest of 21 |
| 6-month return | -22.3% | -13.3% | 8th lowest of 21 |
| Distance from 52-week high | -51.2% | -31.6% | 5th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cullinan Therapeutics CGEM | United States | $728M | -22% | n/a | n/a | n/a | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $725M | +4% | +26% | 61% | 2.7× | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $724M | -16% | +1,079% | 81% | 3.5× | n/a | n/a |
| Ardelyx ARDX | United States | $724M | -58% | +18% | -8% | 1.5× | n/a | n/a |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $716M | -24% | +5% | -30% | 8.7× | n/a | n/a |
| Rigel Pharmaceuticals RIGL | United States | $741M | +52% | +3% | 31% | 2.5× | -1.1% | +22.1% |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $743M | -32% | +7% | 8% | 7.3× | 33.8% | +19.8% |
| Yabao Pharmaceutical 600351.SS | China | $711M | -3% | -3% | 16% | 1.7× | -7.5% | -2.8% |
| Hainan Haiyao 000566.SZ | China | $710M | -19% | -18% | -50% | 11.2× | n/a | n/a |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $705M | -29% | -82% | n/a | 27.3× | 10.5% | -25.1% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $753M | -11% | +4% | 2% | 0.6× | 4.9% | +5.3% |
| Bliss GVS Pharma BLISSGVS.NS | India | $698M | +126% | +21% | 15% | 6.6× | 37.0% | +10.1% |
| Philogen PHIL.MI | Italy | $694M | -7% | +295% | 79% | 0.9× | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $693M | +28% | n/a | n/a | n/a | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $692M | -16% | +23% | 11% | 3.2× | 10.3% | +7.9% |
| Achieve Life Sciences ACHV | United States | $692M | +29% | n/a | n/a | n/a | n/a | n/a |
| Zevra Therapeutics ZVRA | United States | $690M | +4% | +75% | 31% | 3.4× | 0.0% | +51.6% |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $771M | -29% | -16% | 0% | 0.4× | n/a | n/a |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 2.5× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 10.9× | 41.4% | +11.2% |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 0.7× | n/a | n/a |